

Galantos Corporate Fact Sheet

Introduction

Galantos Pharma GmbH is a biopharmaceutical company developing innovative drugs for the treatment of neurodegenerative diseases. At present, its focus is on the improvement of marketed drugs and natural substances for the treatment of Alzheimer's Disease (AD).

The company was founded in 2005 by Profs. Alfred Maelicke (Mainz) and Ulrich Jordis (Vienna) as a spin-off of Maelicke's Laboratory of Molecular Neurobiology at the University of Mainz Medical School, Germany. Galantos has raised a total of EUR 3.5 million in two financing rounds. Memogain, its most advanced product is scheduled to move into clinical trials in 2009 and is expected to be subject to accelerated approval.

Long-standing expertise in Alzheimer's disease

The founders of Galantos Pharma GmbH have a long-standing experience in the neurochemistry of AD and have been proponents of galantamine as a drug to reduce cognitive impairment in AD. Maelicke's laboratory demonstrated, among others, that AD is accompanied by a severe loss of nicotinic acetylcholine receptors (nAChR). It later identified a novel class of nAChR ligands capable of enhancing the activity of remaining nAChRs, the so-called allosteric potentiating ligands (APLs).

Galantamine, which is approved in many countries for the treatment of mild-to-moderate forms of AD, belongs to this drug class. Prof Jordis of Technical University of Vienna developed the first large-scale chemical synthesis for galantamine.

Both Maelicke and Jordis not only acted for many years as advisors for the companies developing galantamine but also explored galantamine as a lead structure for novel AD drugs. Maelicke's research resulted in the patent application on which Galantos Pharma GmbH was based when founded in 2005.

Pipeline

The lead product of Galantos Pharma is Memogain, a derivative of galantamine, which is already marketed for the treatment of AD since 2000 (EU) and 2001 (USA) respectively. Memogain, a prodrug which is metabolized to galantamine in the brain, offers improved efficacy at reduced adverse events and is expected to move into clinical development in Alzheimer's disease (AD) in 2009. It is expected that clinical development and market approval of the pro-galantamine is fast (until 2010/11) and cost effective, as the pharmacologically active compound is approved since 2001 and most clinical data are available and applicable.

In addition, the Company is exploring two novel neuroprotective compounds – an APL targeting nicotinic acetylcholine receptors in general (nAChRs) and a subtype-specific APL targeting the $\alpha 7$ -subunit of nicotinic acetylcholine receptors. APLs enhance the sensitivity of receptors and therefore overcome the well-established shortcomings of direct agonists, which are receptor desensitization and feedback-regulation of expression. Results in animal models indicate that enhancing the sensitivity of nAChRs has considerable therapeutic potential in AD and other CNS-related diseases.

Commercialization Strategy

Galantos' strategy is to achieve a fast and rewarding return of investment for its first project to fund organic growth of the company with follow-on projects.

The Company aims to bring Memogain into clinical development by 2009 and to subsequently license the drug to a pharma partner. Proceeds of this deal shall be used to develop further novel, causal and preventive therapies for AD and other neurological and psychiatric indications based on allosteric modulation of nicotinic receptors and Galantos' existing leads. For these compounds, Galantos aims to form strategic alliances with big pharma partners to reduce development costs and the attrition rate of Alzheimer's medication candidates, creating a stable revenue stream.



Founded

2005

Location

Mainz, Germany

Management

Dr Andreas Köpke (CBO)
Prof Dr Alfred Maelicke (CSO)

Number of Employees

8, of which 5 FTEs

Focus

Neurodegenerative diseases

Indications

Alzheimer's disease (AD),
neuroprotection

Pipeline

Memogain galantamine prodrug
(preclin., Alzheimer's Disease)
nAChR APL (discovery,
neuroprotection)
 $\alpha 7$ nAChR selective APL
(discovery, neuroprotection)

Financing History

€ 3.5 million in two rounds

Investors

Equinet Venture Partners / VRP
Rheinlandpfalz Fonds
KfW
HTGF High-Tech Gründerfond
FIB Fonds of the ISB (Investitions-
und Strukturbank Rheinland-Pfalz)

Business Advisory Board

Dr Farsim Yadegardjam
Dr Bernhard Küenburg
Dr Klaus Binder

Scientific Advisory Board

Prof Dr Ulrich Jordis (Chairman)
Prof Dr Edson Albuquerque
Prof Dr Roger Bullock
Prof Dr Diana Woodruff-Pak
Prof Dr Gregor Fels
Prof Dr Horst Weber
Dr Claus Weichel

More Information:

Galantos Pharma GmbH
Freiligrathstr. 12
D-55131 Mainz
Germany

Tel. +49 (61 31) 1 44 03 11
Fax +49 (61 31) 1 44 03 29
Email info@galantos.com
www.galantos.com